-
Signature
-
/s/ Nathan McConarty, attorney-in-fact
-
Issuer symbol
-
NUVL
-
Transactions as of
-
15 May 2025
-
Net transactions value
-
-$1,127,266
-
Form type
-
4
-
Filing time
-
16 May 2025, 16:30:25 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Porter James Richard |
President and CEO, Director |
C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE |
/s/ Nathan McConarty, attorney-in-fact |
16 May 2025 |
0001862900 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
NUVL |
Class A Common Stock |
Options Exercise |
$751,950 |
+27,000 |
+11% |
$27.85 |
276,062 |
15 May 2025 |
Direct |
F1 |
| transaction |
NUVL |
Class A Common Stock |
Sale |
$1,051,393 |
-15,176 |
-5.5% |
$69.28 |
260,886 |
15 May 2025 |
Direct |
F1, F2 |
| transaction |
NUVL |
Class A Common Stock |
Sale |
$804,115 |
-11,489 |
-4.4% |
$69.99 |
249,397 |
15 May 2025 |
Direct |
F1, F3 |
| transaction |
NUVL |
Class A Common Stock |
Sale |
$23,708 |
-335 |
-0.13% |
$70.77 |
249,062 |
15 May 2025 |
Direct |
F1, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
NUVL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-27,000 |
-12% |
$0.000000 |
204,780 |
15 May 2025 |
Class A Common Stock |
27,000 |
$27.85 |
Direct |
F1, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: